Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
New England Journal of MedicinePublished 22 June 2005Open access
Timothy Winton, Robert B. Livingston, David C. Johnson, James R. Rigas, Michael Johnston, Charles Butts
Citations1,815
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Abstract
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Keywords
Medicine
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
7,727 Citations1958Edward L. Kaplan, Paul Meier
CHEST JournalRevisions in the International System for Staging Lung Cancer
4,598 Citations1997Clifton F. Mountain
Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.
CA A Cancer Journal for CliniciansCancer Statistics, 2004
4,002 Citations2004Ahmedin Jemal, Ram C. Tiwari +6 more
Cancer incidence and mortality rates are lower in other racial and ethnic groups than in Whites and African Americans for all sites combined and for the four major cancer sites, however, these groups generally have higher rates for stomach, liver, and cervical cancers than do Whites.
BMJChemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
2,850 Citations1995Non-small Cell Lung Cancer Collaborative Group
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.
New England Journal of MedicineCisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2,336 Citations2004R. Arriagada
Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer and had a significantly higher survival rate than those assigned to observation.
BiometricsSequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
2,302 Citations1975Stuart Pocock, Richard Simon
A new general procedure for treatment assignment is described which concentrates on minimizing imbalance in the distributions of treatment numbers within the levels of each individual prognostic factor.
Journal of Clinical OncologyRandomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
1,129 Citations2001Karen Kelly, John Crowley +11 more
PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer, and overall costs on the PC arm were higher than on the VC arm because of drug costs.
BiometricsA Confidence Interval for the Median Survival Time
892 Citations1982Ron Brookmeyer, John Crowley
The LancetPostoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials
838 Citations1998Sarah Burdett, Mkb Parmar +17 more
Postoperative radiotherapy is detrimental to patients with early-stage completely resected NSCLC and should not be used routinely for such patients, and subgroup analyses suggest that this adverse effect was greatest for patients with stage I/II, N0-N1 disease.
Journal of Clinical OncologyRandomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
824 Citations1994Thierry Le Chevalier, D. Brisgand +8 more
Since the results have demonstrated that NVB-P yields a longer survival duration and a higher response rate than VDS-P or NVB alone, with acceptable toxicity, this combination should be considered a relevant regimen in advanced NSCLC.
JNCI Journal of the National Cancer InstituteRandomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer
599 Citations2003Giorgio V. Scagliotti
This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC and given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
Journal of Clinical OncologyComparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
595 Citations2000Philip Bonomi, KyungMann Kim +6 more
Paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplarin as the reference regimen in the recently completed phase III trial of paclitaxels in advanced non-small-cell lung cancer.
New England Journal of MedicineA Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
450 Citations2000Steven M. Keller, Sudeshna Adak +7 more
As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.
PubMedNew chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
406 Citations1998Paul A. Bunn, Karen Kelly
Currently available chemotherapy given to non-small cell lung cancers patients with good performance status can improve survival to a similar extent as other solid tumors, such as small cell lung cancer and breast cancer.
European Journal of Cardio-Thoracic SurgeryChemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1
389 Citations2004David Waller, Michael Peake +7 more
This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC, but the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival Benefit with cisplatin-based chemotherapy.
Journal of Clinical OncologyRandomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
367 Citations2004Gary M. Strauss, James E. Herndon +7 more
Adjuvant chemotherapy significantly reduces all-cause and lung cancer mortality in stage IB NSCLC and is the first randomized trial to demonstrate significantly improved survival for a carboplatin-based adjuvant chemotherapy regimen in a uniform population withNSCLC.
Journal of Clinical OncologyRandomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
276 Citations1998Giuseppe Giaccone, Ted A.W. Splinter +11 more
Although survival was not improved, arm B offers a better palliation for advanced NSCLC patients than arm A, and arm B appears superior to arm A with regard to response rate, side effects, and QoL.
PubMedras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
250 Citations1991Tetsuya Mitsudomi, Seth M. Steinberg +7 more
It is concluded that ras mutations, present in a subset of non-small cell lung cancers, are independently associated with the shortened survival of patients, irrespective of treatment intent.
BiometricsExact Confidence Intervals Following a Group Sequential Test
225 Citations1984Anastasios A. Tsiatis, Gary L. Rosner +1 more
A numerical method is used to compute confidence intervals for the mean of a normal distribution following a group sequential test, which uses an ordering of the sample space similar to that employed by Siegmund.
CHEST JournalChemotherapeutic Management of Stage IV Non-small Cell Lung Cancer*
202 Citations2003Mark A. Socinski, David E. Morris +2 more
The data support the fact that properly selected patients benefit from chemotherapy with regard to survival and palliation in both first- line and second-line settings, and it appears that in trials addressing the duration of first-line therapy, this survival and palliative benefit occurs early, and prolonged therapy is not indicated.
PubMedras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
167 Citations1992Kenji Sugio, Tatsuhiro Ishida +4 more
Lung CancerPrognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients
156 Citations1994Rafael Rosell, Shuang Li +8 more
K-ras point mutation positive subset had poorer survival, nine of the 13 patients died during the follow-up period as compared with 22 of 53 patients with no mutation in the K-ras gene (P = 0.01), the difference was also strikingly significant when stratified according to node status.
BMJChemotherapy for non-small cell lung cancer
151 Citations1995David P. Carbone, J. D Minna
A meta-analysis of updated data from 9387 patients participating in 52 randomised clinical trials comparing chemotherapy with no chemotherapy suggests that the benefits of chemotherapy of non-small cell lung cancer are small.
Lung CancerCompliance with post-operative adjuvant chemotherapy in non-small cell lung cancer
134 Citations2004Naveed Alam, Frances A. Shepherd +8 more
Patients randomized in Canada were more likely to fail to complete chemotherapy due to refusal of therapy than their American counterparts and differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further.
The LancetOndansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis
76 Citations1992Italian Group For Antiemetic Research
PubMedAngiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
46 Citations1997Ming‐Sound Tsao, Ni Liu +3 more
It is suggested that VEGF is a major angiogenesis factor in NSCLC but that other factors beside ras mutations may influence tumor vascularity in these tumors, and that the two parameters may potentially serve as independent prognostic factors inNSCLC.
Lung CancerThe influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer
44 Citations2002S.M. Keller, Márk Vangel +9 more
Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC, however, women with non-squamous histology have increased survival when compared to men.
Surgical Treatment for Non-small Cell Lung Cancer
33 Citations2013Chadrick E. Denlinger
The expected survival following surgical resection is substantially better than the observed survival among patients who decline any type of treatment modality, and ongoing studies in the future will compare the relative efficacy of surgical resections with other emerging treatment modalities.
Annals of OncologyIs cisplatin still the best platinum compound in non-small-cell lung cancer?
23 Citations2002Jean‐Charles Soria, Thierry Le Chevalier
ThoraxLung cancer * 4: Chemotherapy for non-small cell lung cancer: the end of the beginning
20 Citations2003M.H. Cullen
Journal of Clinical OncologyAre cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients
20 Citations2004Naseem J. Zojwalla, Harry Raftopoulos +1 more
Journal of Clinical OncologyAre cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients
13 Citations2004N. J. Zojwalla, Harry Raftopoulos +1 more
A modest but useful survival benefit favors cisplatin, similar to the benefit of chemo over BSC with older regimens, and comprises a more important benefit than the choice of the new agent in a doublet.